EPCORE DLBCL-2: This study is comparing the safety and effectiveness of two treatment regimens that both involve targeted therapies and chemotherapy in people with newly diagnosed Diffuse Large B-Cell LymphomaA Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Summary

Eligible participants will be randomly allocated to one of two treatment arms. In Arm 1, participants will receive a new targeted therapy (called epcoritamab) combined with R-CHOP treatment. R-CHOP involves targeted therapy (called rituximab) plus chemotherapy (cyclophosphamide, vincristine and doxorubicin) and a steroid (called prednisone). This will then be followed by further epcoritamab. In Arm 2, participants will receive R-CHOP followed by further rituximab. Epcoritamab will be administered via subcutaneous injection. Cyclophosphamide, rituximab, vincristine and doxorubicin will be administered via intravenous (IV) infusion. Prednisone will be administered as an oral tablet.